Acquired Resistance to Treatment With Arvin

Pitney, W. R.; Bray, Colin J.; Holt, P J; Bolton, G C

doi:10.1016/s0140-6736(69)91093-9

Cited by 31 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This might be due to an immune interaction with the venom. A similar tolerance has previously been observed in patients who were repeatedly treated with the venom of Agkistrodon rhodostoma (Arvin) (20). Still, the modified response in this patient might constitute an argument for the assumption that the changes in the hemophilic group were indeed related to the snake venom enzyme itself and not to other factors of the experimental procedure.…”

Section: Discussionsupporting

confidence: 83%

“…The hemophilic patient J.E. was not included in t he calculations for group III because in contrast to the other patients he had previously received multiple injections of a less purified Reptilase preparation for hemostatic purposes, and since acquired resistance to the clot-promoting effect of snake venoms has previously been observed (20).…”

Section: H Emophilic Individuals (Group Iii)mentioning

confidence: 99%

See 1 more Smart Citation

Reptilase-Induced Shortening of Coagulation Times in Normal and Hemophilic Individuals

Aj¹,

Stadelmann²,

Pw³

1972

Thromb Haemost

View full text Add to dashboard Cite

SummaryIn 5 normal volunteers infusion of small doses of Reptilase-def., a thrombin-like snake venom enzyme of Bothrops atrox, led to a transient shortening of the clotting time, which was significant when compared with a control group infused with glucose. In hemophilic individuals, clotting and recalcification times were also considerably shortened, the maximal effect in both groups occurring simultaneously with cryoprecipitability and positive paracoagulation phenomena. Whether this accelerating effect on blood coagulation is mediated by circulating soluble fibrin complexes, is not yet established. However, the clot-promoting action of Reptilase must predominantly be localized at the level of fibrinogen/fibrin conversion rather than in earlier phases of coagulation.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: H Emophilic Individuals (Group Iii)mentioning

confidence: 99%

Reptilase-Induced Shortening of Coagulation Times in Normal and Hemophilic Individuals

Aj¹,

Stadelmann²,

Pw³

1972

Thromb Haemost

View full text Add to dashboard Cite

show abstract

“…Fifty six days after stopping Arvin, there was still in vitro evidence of resistance using a modification of the test described by Pitney et al , (1969) where fibrinogen titres were measured. Using patients serum.…”

Section: Case Reportmentioning

confidence: 99%

“…The duration of therapy with the anticoagulant “Arvin” may be limited by acquired resistance, the patient developing specific anti‐bodies when the drug is given intramuscularly, subcutaneously or intravenously (Pitney et al , 1969). We report the case of a patient with recurrent thrombo‐embolic disease who was given intravenous Arvin for a total of 45 days before developing resistance.…”

mentioning

confidence: 99%

Acquired Resistance to Prolonged Treatment with Intravenous “Arvin” (Ancrod)

Thomson

Eon

Dagg

1976

Int J Clinical Practice

View full text Add to dashboard Cite

The duration of therapy with the anticoagulant "Arvin" may be limited by acquired resistance, the patient developing specific anti-bodies when the drug is given intramuscularly. subcutaneously or intravenously (Pitney et al.. 1969). We report the case of a patient with recurrent thrombo-embolic disease who was given intravenous Arvin for a total of 45 days before developing resistance. There were no signs of an allergic reaction associated with this resistance.

show abstract

“…Since ancrod is a polypeptide of a molecular weight of about 30.000 the possibility of the development of antibodies has been considered (Pitney et al 1969). Clinical resistance to ancrod was demonstrated in two patients in whom attempts were made to anticoagulate them by a second course of this substance.…”

Section: Introductionmentioning

confidence: 99%

Acquired Resistance to Ancrod Its Evaluation and Clinical Occurrence

Vinazzer¹

1973

Thromb Haemost

View full text Add to dashboard Cite

SummaryA simple test for the detection and quantitation of resistance to ancrod is described. The test is based on the polymerization of fibrinogen by ancrod. The possible variables of the method such as the concentration of fibrinogen, the adsorption of ancrod onto a normal serum protein and the kinetics of the reaction between ancrod and the inactivating substance are examined. By this method, in 4 out of 19 patients who had previously received ancrod, resistance could be detected up to 15 months after therapy. In one of those patients, a second series of doses of ancrod was given. When the dose was elevated to an extent corresponding to the concentration of the inactivating substance, hypofibrinogenemia could be promptly established. The clinical importance of the test is discussed.

show abstract

Acquired Resistance to Treatment With Arvin

Cited by 31 publications

References 9 publications

Reptilase-Induced Shortening of Coagulation Times in Normal and Hemophilic Individuals

Reptilase-Induced Shortening of Coagulation Times in Normal and Hemophilic Individuals

Acquired Resistance to Prolonged Treatment with Intravenous “Arvin” (Ancrod)

Acquired Resistance to Ancrod Its Evaluation and Clinical Occurrence

Contact Info

Product

Resources

About